Bartlett DL - Search Results

1

250 robotic pancreatic resections: safety and feasibility.

Zureikat AH, Moser AJ, Boone BA, Bartlett DL, Zenati M, Zeh HJ 3rd. Zureikat AH, et al. Among authors: bartlett dl. Ann Surg. 2013 Oct;258(4):554-9; discussion 559-62. doi: 10.1097/SLA.0b013e3182a4e87c. Ann Surg. 2013. PMID: 24002300 Free PMC article.

2

Operative management of islet-cell tumors arising in the head of the pancreas.

Park BJ, Alexander HR, Libutti SK, Huang J, Royalty D, Skarulis MC, Jensen RT, Gorden P, Doppman JL, Shawker TH, Fraker DL, Norton JA, Bartlett DL. Park BJ, et al. Among authors: bartlett dl. Surgery. 1998 Dec;124(6):1056-61; discussion 1061-2. doi: 10.1067/msy.1998.92171. Surgery. 1998. PMID: 9854583

3

Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers.

Zeh HJ, Bartlett DL. Zeh HJ, et al. Among authors: bartlett dl. Cancer Gene Ther. 2002 Dec;9(12):1001-12. doi: 10.1038/sj.cgt.7700549. Cancer Gene Ther. 2002. PMID: 12522439 Review.

4

Pancreaticoduodenectomy in the presence of superior mesenteric venous obstruction.

Koniaris LG, Staveley-O'Carroll KF, Zeh HJ, Perez E, Jin XL, Maley WR, Zabari G, Bartlett DL, Khanna A, Franceschi D, Schoeniger LO. Koniaris LG, et al. Among authors: bartlett dl. J Gastrointest Surg. 2005 Sep-Oct;9(7):915-21. doi: 10.1016/j.gassur.2005.04.005. J Gastrointest Surg. 2005. PMID: 16137584

5

Natural killer-dendritic cell cross-talk in cancer immunotherapy.

Kalinski P, Mailliard RB, Giermasz A, Zeh HJ, Basse P, Bartlett DL, Kirkwood JM, Lotze MT, Herberman RB. Kalinski P, et al. Among authors: bartlett dl. Expert Opin Biol Ther. 2005 Oct;5(10):1303-15. doi: 10.1517/14712598.5.10.1303. Expert Opin Biol Ther. 2005. PMID: 16197336 Review.

6

The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2.

Guo ZS, Naik A, O'Malley ME, Popovic P, Demarco R, Hu Y, Yin X, Yang S, Zeh HJ, Moss B, Lotze MT, Bartlett DL. Guo ZS, et al. Among authors: bartlett dl. Cancer Res. 2005 Nov 1;65(21):9991-8. doi: 10.1158/0008-5472.CAN-05-1630. Cancer Res. 2005. PMID: 16267024

7

High mobility group B1 protein suppresses the human plasmacytoid dendritic cell response to TLR9 agonists.

Popovic PJ, DeMarco R, Lotze MT, Winikoff SE, Bartlett DL, Krieg AM, Guo ZS, Brown CK, Tracey KJ, Zeh HJ 3rd. Popovic PJ, et al. Among authors: bartlett dl. J Immunol. 2006 Dec 15;177(12):8701-7. doi: 10.4049/jimmunol.177.12.8701. J Immunol. 2006. PMID: 17142771

8

Multianalyte profiling of serum cytokines for detection of pancreatic cancer.

Zeh HJ, Winikoff S, Landsittel DP, Gorelik E, Marrangoni AM, Velikokhatnaya L, Winans MT, Lee K, Moser A, Bartlett D, Lotze MT, Siegfried JM, Whitcomb D, Papacristou G, Slivka A, Bigbee WL, Lokshin AE. Zeh HJ, et al. Cancer Biomark. 2005;1(6):259-69. doi: 10.3233/cbm-2005-1601. Cancer Biomark. 2005. PMID: 17192050

9

A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.

Yang S, Guo ZS, O'Malley ME, Yin X, Zeh HJ, Bartlett DL. Yang S, et al. Among authors: bartlett dl. Gene Ther. 2007 Apr;14(8):638-47. doi: 10.1038/sj.gt.3302914. Epub 2007 Feb 1. Gene Ther. 2007. PMID: 17268533

10

High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy.

Dong Xda E, Ito N, Lotze MT, Demarco RA, Popovic P, Shand SH, Watkins S, Winikoff S, Brown CK, Bartlett DL, Zeh HJ 3rd. Dong Xda E, et al. Among authors: bartlett dl. J Immunother. 2007 Sep;30(6):596-606. doi: 10.1097/CJI.0b013e31804efc76. J Immunother. 2007. PMID: 17667523

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

410 results

Search Page

Filters